Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The British Association of Dermatologists' Biologic Interventions Register (BADBIR) in patients with severe psoriasis

Next Previous
Trial Profile

The British Association of Dermatologists' Biologic Interventions Register (BADBIR) in patients with severe psoriasis

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 29 Sep 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adalimumab (Primary) ; Etanercept (Primary) ; Guselkumab (Primary) ; Secukinumab (Primary) ; Ustekinumab (Primary) ; Acitretin; Ciclosporin; Fumaric acid; Hydroxycarbamide; Infliximab; Ixekizumab; Methotrexate; Psoralens
  • Indications Plaque psoriasis; Psoriatic arthritis
  • Focus Therapeutic Use
  • Acronyms BADBIR; BADBIR

    • Most Recent Events

    • 28 Aug 2022 Results (n= 6,607 ) assessing PsA, nail involvement, previous biologic exposure, and ethnicity as factors that have a differential effect on drug survival dependent on the choice of biologic therapy, presented at the 38th International Conference on Pharmacoepidemiology and Therapeutic Risk Management
    • 05 Jun 2021 Data from this study was used to evaluate the baseline characteristics and comorbidities in PsO patients with and without a PsA diagnosis presented at the 22nd Annual Congress of the European League Against Rheumatism.
    • 02 Dec 2020 Results (n=1231) assessing the comparative effectiveness of ustekinumab and secukinumab in patients with psoriasis, and the relative effectiveness estimate of the CLEAR trial, published in the JAMA Dermatology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top